21 research outputs found

    Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.

    Get PDF
    Scavenger receptor BI (SR-BI) is the major receptor for high-density lipoprotein (HDL) cholesterol (HDL-C). In humans, high amounts of HDL-C in plasma are associated with a lower risk of coronary heart disease (CHD). Mice that have depleted Scarb1 (SR-BI knockout mice) have markedly elevated HDL-C levels but, paradoxically, increased atherosclerosis. The impact of SR-BI on HDL metabolism and CHD risk in humans remains unclear. Through targeted sequencing of coding regions of lipid-modifying genes in 328 individuals with extremely high plasma HDL-C levels, we identified a homozygote for a loss-of-function variant, in which leucine replaces proline 376 (P376L), in SCARB1, the gene encoding SR-BI. The P376L variant impairs posttranslational processing of SR-BI and abrogates selective HDL cholesterol uptake in transfected cells, in hepatocyte-like cells derived from induced pluripotent stem cells from the homozygous subject, and in mice. Large population-based studies revealed that subjects who are heterozygous carriers of the P376L variant have significantly increased levels of plasma HDL-C. P376L carriers have a profound HDL-related phenotype and an increased risk of CHD (odds ratio = 1.79, which is statistically significant)

    Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci

    Get PDF
    Smoking is a major heritable and modifiable risk factor for many diseases, including cancer, common respiratory disorders and cardiovascular diseases. Fourteen genetic loci have previously been associated with smoking behaviour-related traits. We tested up to 235,116 single nucleotide variants (SNVs) on the exome-array for association with smoking initiation, cigarettes per day, pack-years, and smoking cessation in a fixed effects meta-analysis of up to 61 studies (up to 346,813 participants). In a subset of 112,811 participants, a further one million SNVs were also genotyped and tested for association with the four smoking behaviour traits. SNV-trait associations withP <5 x 10(-8)in either analysis were taken forward for replication in up to 275,596 independent participants from UK Biobank. Lastly, a meta-analysis of the discovery and replication studies was performed. Sixteen SNVs were associated with at least one of the smoking behaviour traits (P <5 x 10(-8)) in the discovery samples. Ten novel SNVs, including rs12616219 nearTMEM182, were followed-up and five of them (rs462779 inREV3L, rs12780116 inCNNM2, rs1190736 inGPR101, rs11539157 inPJA1, and rs12616219 nearTMEM182) replicated at a Bonferroni significance threshold (P <4.5 x 10(-3)) with consistent direction of effect. A further 35 SNVs were associated with smoking behaviour traits in the discovery plus replication meta-analysis (up to 622,409 participants) including a rare SNV, rs150493199, inCCDC141and two low-frequency SNVs inCEP350andHDGFRP2. Functional follow-up implied that decreased expression ofREV3Lmay lower the probability of smoking initiation. The novel loci will facilitate understanding the genetic aetiology of smoking behaviour and may lead to the identification of potential drug targets for smoking prevention and/or cessation.Peer reviewe

    New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475,000 Individuals

    Get PDF
    Background - Genome-wide association studies have recently identified &gt;400 loci that harbor DNA sequence variants that influence blood pressure (BP). Our earlier studies identified and validated 56 single nucleotide variants (SNVs) associated with BP from meta-analyses of exome chip genotype data. An additional 100 variants yielded suggestive evidence of association. Methods and Results - Here, we augment the sample with 140 886 European individuals from the UK Biobank, in whom 77 of the 100 suggestive SNVs were available for association analysis with systolic BP or diastolic BP or pulse pressure. We performed 2 meta-analyses, one in individuals of European, South Asian, African, and Hispanic descent (pan-ancestry, ≈475 000), and the other in the subset of individuals of European descent (≈423 000). Twenty-one SNVs were genome-wide significant (P&lt;5×10-8) for BP, of which 4 are new BP loci: rs9678851 (missense, SLC4A1AP), rs7437940 (AFAP1), rs13303 (missense, STAB1), and rs1055144 (7p15.2). In addition, we identified a potentially independent novel BP-associated SNV, rs3416322 (missense, SYNPO2L) at a known locus, uncorrelated with the previously reported SNVs. Two SNVs are associated with expression levels of nearby genes, and SNVs at 3 loci are associated with other traits. One SNV with a minor allele frequency &lt;0.01, (rs3025380 at DBH) was genome-wide significant. Conclusions - We report 4 novel loci associated with BP regulation, and 1 independent variant at an established BP locus. This analysis highlights several candidate genes with variation that alter protein function or gene expression for potential follow-up

    Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use

    No full text
    Background: Smoking and alcohol use have been associated with common genetic variants in multiple loci. Rare variants within these loci hold promise in the identification of biological mechanisms in substance use. Exome arrays and genotype imputation can now efficiently genotype rare nonsynonymous and loss of function variants. Such variants are expected to have deleterious functional consequences and to contribute to disease risk. Methods: We analyzed ∼250,000 rare variants from 16 independent studies genotyped with exome arrays and augmented this dataset with imputed data from the UK Biobank. Associations were tested for five phenotypes: cigarettes per day, pack-years, smoking initiation, age of smoking initiation, and alcoholic drinks per week. We conducted stratified heritability analyses, single-variant tests, and gene-based burden tests of nonsynonymous/loss-of-function coding variants. We performed a novel fine-mapping analysis to winnow the number of putative causal variants within associated loci. Results: Meta-analytic sample sizes ranged from 152,348 to 433,216, depending on the phenotype. Rare coding variation explained 1.1% to 2.2% of phenotypic variance, reflecting 11% to 18% of the total single nucleotide polymorphism heritability of these phenotypes. We identified 171 genome-wide associated loci across all phenotypes. Fine mapping identified putative causal variants with double base-pair resolution at 24 of these loci, and between three and 10 variants for 65 loci. Twenty loci contained rare coding variants in the 95% credible intervals. Conclusions: Rare coding variation significantly contributes to the heritability of smoking and alcohol use. Fine-mapping genome-wide association study loci identifies specific variants contributing to the biological etiology of substance use behavior

    Data Related to Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci

    No full text
    Here we have included four sets of meta-analysis results: Meta-analysis of discovery and replication cohorts, combining genotyped Exome-chip and Axiom array content for (i) Smoking Initiation, (ii) Cigarettes per day, and (iii) Smoking Cessation, and (iv) meta-analysis of discovery cohorts for Pack Years.Smoking is a major heritable and modifiable risk factor for many diseases, including cancer, common respiratory disorders and cardiovascular diseases. We tested up to 235,116 single nucleotide variants (SNVs) on the exome-array for association with smoking initiation, cigarettes per day, pack-years, and smoking cessation in a fixed effects meta-analysis of up to 61 studies (up to 346,813 participants). SNV-trait associations with P < 5 × 10−8 in either analysis were taken forward for replication in up to 275,596 independent participants from UK Biobank. Lastly, a meta-analysis of the discovery and replication studies was performed. These novel loci will facilitate understanding the genetic aetiology of smoking behaviour and may lead to the identification of potential drug targets for smoking prevention and/or cessation

    New blood pressure-associated loci identified in meta-analyses of 475 000 individuals

    No full text
    Genome-wide association studies have recently identified &gt;400 loci that harbor DNA sequence variants that influence blood pressure (BP). Our earlier studies identified and validated 56 single nucleotide variants (SNVs) associated with BP from meta-analyses of exome chip genotype data. An additional 100 variants yielded suggestive evidence of association.Here, we augment the sample with 140 886 European individuals from the UK Biobank, in whom 77 of the 100 suggestive SNVs were available for association analysis with systolic BP or diastolic BP or pulse pressure. We performed 2 meta-analyses, one in individuals of European, South Asian, African, and Hispanic descent (pan-ancestry, ≈475 000), and the other in the subset of individuals of European descent (≈423 000). Twenty-one SNVs were genome-wide significant (P&lt;5×10-8) for BP, of which 4 are new BP loci: rs9678851 (missense, SLC4A1AP), rs7437940 (AFAP1), rs13303 (missense, STAB1), and rs1055144 (7p15.2). In addition, we identified a potentially independent novel BP-associated SNV, rs3416322 (missense, SYNPO2L) at a known locus, uncorrelated with the previously reported SNVs. Two SNVs are associated with expression levels of nearby genes, and SNVs at 3 loci are associated with other traits. One SNV with a minor allele frequency &lt;0.01, (rs3025380 at DBH) was genome-wide significant.We report 4 novel loci associated with BP regulation, and 1 independent variant at an established BP locus. This analysis highlights several candidate genes with variation that alter protein function or gene expression for potential follow-up

    Genetic invalidation of Lp-PLA(2) as a therapeutic target : Large-scale study of five functional Lp-PLA(2)-lowering alleles

    Get PDF
    Aims: Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), has not reduced risk of cardiovascular disease outcomes in recent randomized trials. We aimed to test whether Lp-PLA(2) enzyme activity is causally relevant to coronary heart disease. Methods: In 72,657 patients with coronary heart disease and 110,218 controls in 23 epidemiological studies, we genotyped five functional variants: four rare loss-of-function mutations (c. 109+2T> C (rs142974898), Arg82His (rs144983904), Val279Phe (rs76863441), Gln287Ter (rs140020965)) and one common modest-impact variant (Val379Ala (rs1051931)) in PLA2G7, the gene encoding Lp-PLA(2). We supplemented de-novo genotyping with information on a further 45,823 coronary heart disease patients and 88,680 controls in publicly available databases and other previous studies. We conducted a systematic review of randomized trials to compare effects of darapladib treatment on soluble Lp-PLA(2) activity, conventional cardiovascular risk factors, and coronary heart disease risk with corresponding effects of Lp-PLA(2)-lowering alleles. Results: Lp-PLA(2) activity was decreased by 64% (p = 2.4 x 10 (-25)) with carriage of any of the four loss-of-function variants, by 45% (p<10 (-300)) for every allele inherited at Val279Phe, and by 2.7% (p = 1.9 x 10 (-12)) for every allele inherited at Val379Ala. Darapladib 160 mg once-daily reduced Lp-PLA(2) activity by 65% (p<10 (-300)). Causal risk ratios for coronary heart disease per 65% lower Lp-PLA(2) activity were: 0.95 (0.88-1.03) with Val279Phe; 0.92 (0.74-1.16) with carriage of any loss-of-function variant; 1.01 (0.68-1.51) with Val379Ala; and 0.95 (0.89-1.02) with darapladib treatment. Conclusions: In a large-scale human genetic study, none of a series of Lp-PLA(2)-lowering alleles was related to coronary heart disease risk, suggesting that Lp-PLA(2) is unlikely to be a causal risk factor.Peer reviewe

    Selvitys toiminnanohjausjärjestelmistä ja niiden käyttöönotosta U-landshjälp från Folk till Folk i Finland rf:lle

    Get PDF
    Tämän opinnäytetyön aiheena oli selvittää, mitä on otettava huomioon toiminnanohjausjärjestelmää hankkiessa ja millainen olisi sopivin. Työn tilaaja oli Nurmijärvellä Klaukkalassa toimiva U-landshjälp från Folk till Folk i Finland rf, kansankielellä UFF. Yhdistys kerää lahjoitusvaatteita ympäri Suomea kehitysapukohteidensa avustamiseksi. Tavoitteena opinnäytetyössä oli luoda kattava ohje tukemaan päätöstä toiminnanohjausjärjestelmän hankkimiseksi. Opinnäytetyö rajattiin käsittelemään toiminnanohjausjärjestelmän hankinnan kannalta tärkeisiin teorioihin ja käyttöönottoon sekä vertailevaan analyysiin muutamasta markkinoilla olevista järjestelmästä. Opinnäytetyö aloitettiin perehtymällä toiminnanohjausjärjestelmien teoriaan ja käyttöönot-toon sekä UFF:n toimintaan kattavasti. Tietolähteinä käytettiin haastatteluja, alan kirjallisuutta sekä ohjelmistotalojen esitelmiä. Opinnäytetyön alussa käsitellään toiminnanohjausjärjestelmien toiminta ja teoria monipuolisesti ja perusteellisesti. Tämän jälkeen käydään kattavasti UFF:n historia, luvut ja toiminta vaihe vaiheelta. Seuraavassa osiossa pohditaan, miten toiminnanohjausjärjestelmän käyttöönotto vaikuttaisi UFF:n keräystoimintaan. Lopussa esitellään valitut vaihtoehdot toiminnanohjausjärjestelmäksi UFF:lle ja vertaillaan näitä pistetaulukon avulla. Lopputuloksen jälkeen pohditaan vielä, mitkä voisivat olla UFF:n seuraavat loogiset kehityskohteet tämän toiminnan parantamiseksi tulevaisuudessa. Toiminnanohjausjärjestelmän löytäminen UFF:n kaltaiselle yhdistykselle loi monia kriteerejä ja vaatimuksia verrattuna tavallisiin kuljetusyrityksiin. Toiminta oli kuitenkin helposti verrattavissa jätealan kuljetustoimintaan, jota käytetiin vertailuja tehdessä referenssinä. Tämä opinnäytetyö antaa kattavan tietopaketin toiminnanohjausjärjestelmän valintaan ja sen hankintaan. Työn tilaajaa ja toiminnanohjausjärjestelmän valintaa koskeva osuus on luovutettu vain työn tilaajan käyttöön.The objective of this Bachelors’ thesis was to determine what needs to be taken into ac-count when acquiring and implementing an ERP in a company and finding the most suitable system. This thesis was commissioned by U-landshjälp från Folk till Folk i Finland rf, commonly known as UFF. The organization collects donated clothes all around Finland to aid their development cooperation. The goal for this thesis was to create a comprehensive guide to support the decision to procure and ERP. The thesis covers the vital theories regarding the ERP and its implementation and a comparative analysis of a few software systems on the market. The study was started by familiarizing with the theories and implementation of an ERP and taking a close look on how UFF operates. The data was gathered by interviews, literature and presentations from software companies. Firstly, the principles and theories of ERP were covered diversely and thoroughly. Secondly, the history, key figures and the operation of UFF were detailed step by step. In the next section, it was examined how the implementation of an ERP would affect the collection of donations in UFF. After this, a few potential software companies and their software systems were showcased and compared to find the most suitable ERP for UFF using a score chart. Finally, it was discussed on what could be the next step to improve the operations of UFF in the future. Finding an ERP for UFF created certain criteria and demands compared to the more traditional transport companies. Operations are correlative with garbage transportations and this was used as a basis when making references. This thesis contains a comprehensive amount of information when choosing, procuring and implementing an ERP and suggests a few alternative solutions. The sections concerning the organization and the ERP selection have been made available only for the client
    corecore